{"schemaVersion":"peptidescanner-evidence-bundle/v1","canonicalUrl":"https://peptidescanner.com/evidence/v1/peptides/sermorelin.json","manifestUrl":"https://peptidescanner.com/evidence/v1/manifest.json","peptide":{"slug":"sermorelin","name":"Sermorelin","url":"https://peptidescanner.com/peptides/sermorelin/"},"addressing":"objects is keyed by objectPathId. A URL fragment #<objectPathId> on this file names one evidence object. Every version of a record is placed in the bundle of the record's current first peptide.","objectCount":5,"objects":{"fda-drugs-nda019863-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:fda-drugs-nda019863:v1","objectPathId":"fda-drugs-nda019863-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/fda-drugs-nda019863/","json":"https://peptidescanner.com/evidence/v1/peptides/sermorelin.json#fda-drugs-nda019863-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/sermorelin.md#fda-drugs-nda019863-v1"},"story":{"slug":"fda-drugs-nda019863","version":1,"domain":"Regulatory","dateInSource":"1990-12-28","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["sermorelin"],"peptides":[{"slug":"sermorelin","url":"https://peptidescanner.com/peptides/sermorelin/"}]},"claims":[{"id":"headline","text":"Drugs@FDA application NDA019863","sourceIds":["fda-drugs-nda019863-1990-12-28-e8b206cc80df"]},{"id":"summary","text":"The official Drugs@FDA dataset lists original submission 1 for NDA 019863 with status AP dated 1990-12-28, and names sermorelin acetate among the application record's active ingredients.","sourceIds":["fda-drugs-nda019863-1990-12-28-e8b206cc80df"]},{"id":"paragraph-1","text":"The official Drugs@FDA dataset lists original submission 1 for NDA 019863 with status AP dated 1990-12-28, and names sermorelin acetate among the application record's active ingredients.","sourceIds":["fda-drugs-nda019863-1990-12-28-e8b206cc80df"]},{"id":"paragraph-2","text":"This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance.","sourceIds":["fda-drugs-nda019863-1990-12-28-e8b206cc80df"]}],"sources":[{"id":"fda-drugs-nda019863-1990-12-28-e8b206cc80df","name":"Drugs@FDA via openFDA","sourceClass":"A","title":"Drugs@FDA application NDA019863 · original submission status AP · 1990-12-28 · dataset 2026-11-13","url":"https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA019863%22&limit=1"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"7cddc7b38733c05e23acc0911db99bfa1fb983ec060b863d66c4d9331f41b2d4","tierARecordSha256":"e8b206cc80dfdc04c4d753e8b51985edbefc12226a997a9803a92f40e3ad5382"},"integrity":{"algorithm":"sha256","contentSha256":"10d6c2677c588683b7fabda63af96877985f43284e1b72527592b486290e04cf"}},"fda-drugs-nda020443-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:fda-drugs-nda020443:v1","objectPathId":"fda-drugs-nda020443-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/fda-drugs-nda020443/","json":"https://peptidescanner.com/evidence/v1/peptides/sermorelin.json#fda-drugs-nda020443-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/sermorelin.md#fda-drugs-nda020443-v1"},"story":{"slug":"fda-drugs-nda020443","version":1,"domain":"Regulatory","dateInSource":"1997-09-26","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["sermorelin"],"peptides":[{"slug":"sermorelin","url":"https://peptidescanner.com/peptides/sermorelin/"}]},"claims":[{"id":"headline","text":"Drugs@FDA application NDA020443","sourceIds":["fda-drugs-nda020443-1997-09-26-957ec2aa11e7"]},{"id":"summary","text":"The official Drugs@FDA dataset lists original submission 1 for NDA 020443 with status AP dated 1997-09-26, and names sermorelin acetate among the application record's active ingredients.","sourceIds":["fda-drugs-nda020443-1997-09-26-957ec2aa11e7"]},{"id":"paragraph-1","text":"The official Drugs@FDA dataset lists original submission 1 for NDA 020443 with status AP dated 1997-09-26, and names sermorelin acetate among the application record's active ingredients.","sourceIds":["fda-drugs-nda020443-1997-09-26-957ec2aa11e7"]},{"id":"paragraph-2","text":"This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance.","sourceIds":["fda-drugs-nda020443-1997-09-26-957ec2aa11e7"]}],"sources":[{"id":"fda-drugs-nda020443-1997-09-26-957ec2aa11e7","name":"Drugs@FDA via openFDA","sourceClass":"A","title":"Drugs@FDA application NDA020443 · original submission status AP · 1997-09-26 · dataset 2026-11-13","url":"https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA020443%22&limit=1"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"13621a3c41c5e400e43b8d093493da86bdcb688bdf1463f4b57aa3668998a3cc","tierARecordSha256":"957ec2aa11e74ea78dcccbb852ee58d2a002b7eacc21230bbca28afc2e8aa6c9"},"integrity":{"algorithm":"sha256","contentSha256":"d0a71836c039819d61741cc85a966a59589fe3b111eac7e00d1e497e40292cc8"}},"federal-register-2013-04827-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:federal-register-2013-04827:v1","objectPathId":"federal-register-2013-04827-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/federal-register-2013-04827/","json":"https://peptidescanner.com/evidence/v1/peptides/sermorelin.json#federal-register-2013-04827-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/sermorelin.md#federal-register-2013-04827-v1"},"story":{"slug":"federal-register-2013-04827","version":1,"domain":"Regulatory","dateInSource":"2013-03-04","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["sermorelin"],"peptides":[{"slug":"sermorelin","url":"https://peptidescanner.com/peptides/sermorelin/"}]},"claims":[{"id":"headline","text":"Federal Register notice 2013-04827","sourceIds":["federal-register-2013-04827-72d90717f32d"]},{"id":"summary","text":"The Federal Register published notice 2013-04827, attributed to FDA and its parent HHS department, on 2013-03-04. Its official title is “Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Sermorelin.","sourceIds":["federal-register-2013-04827-72d90717f32d"]},{"id":"paragraph-1","text":"The Federal Register published notice 2013-04827, attributed to FDA and its parent HHS department, on 2013-03-04. Its official title is “Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Sermorelin.","sourceIds":["federal-register-2013-04827-72d90717f32d"]},{"id":"paragraph-2","text":"This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use.","sourceIds":["federal-register-2013-04827-72d90717f32d"]}],"sources":[{"id":"federal-register-2013-04827-72d90717f32d","name":"Federal Register via GovInfo","sourceClass":"A","title":"Federal Register notice 2013-04827 · published 2013-03-04 · Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness","url":"https://www.govinfo.gov/content/pkg/FR-2013-03-04/pdf/2013-04827.pdf"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"2b17fe7823daeec002bd82f9b0a029a153500bbc8385deb6a2f4ff1f4c1643fe","tierARecordSha256":"72d90717f32dc537af1a4156da96d1d2d322648a6858cd92d5f4d2de5dba05bf"},"integrity":{"algorithm":"sha256","contentSha256":"946402240d930a604a251c0d1db1b4ba11060791c5c79473f4f0b1426410914d"}},"pubmed-pmid-18031173-sermorelin-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-18031173-sermorelin:v1","objectPathId":"pubmed-pmid-18031173-sermorelin-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-18031173-sermorelin/","json":"https://peptidescanner.com/evidence/v1/peptides/sermorelin.json#pubmed-pmid-18031173-sermorelin-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/sermorelin.md#pubmed-pmid-18031173-sermorelin-v1"},"story":{"slug":"pubmed-pmid-18031173-sermorelin","version":1,"domain":"Literature metadata","dateInSource":"2018-10-25","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["sermorelin"],"peptides":[{"slug":"sermorelin","url":"https://peptidescanner.com/peptides/sermorelin/"}]},"claims":[{"id":"headline","text":"Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.","sourceIds":["pubmed-observation-pmid-18031173-2018-10-25-ce9838a7f831"]},{"id":"summary","text":"PubMed lists PMID 18031173 in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy as Journal Article, with publication-date metadata of 1999-08 (month precision). PeptideScanner associated the retained record with the identity slug sermorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-18031173-2018-10-25-ce9838a7f831"]},{"id":"paragraph-1","text":"PubMed lists PMID 18031173 in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy as Journal Article, with publication-date metadata of 1999-08 (month precision). PeptideScanner associated the retained record with the identity slug sermorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-18031173-2018-10-25-ce9838a7f831"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-18031173-2018-10-25-ce9838a7f831"]}],"sources":[{"id":"pubmed-observation-pmid-18031173-2018-10-25-ce9838a7f831","name":"PubMed","sourceClass":"A","title":"Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. · retained source version 1:2018-10-25:current:ce9838a7f8311731f957921bfe5963757aee3486dc6fbb1272aad56e35393d3c","url":"https://pubmed.ncbi.nlm.nih.gov/18031173/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"0e385d9317043906602095d6fe43eae2b7bb064527bd7ba20489e436b1b42636","tierARecordSha256":"4f35352b5cd4ea95127370594c053639959b6c671469a625ada48b2bb54b5a47"},"integrity":{"algorithm":"sha256","contentSha256":"dc855ca2be06b671f9da0b0392cf06f7b4f0820e5127400f143a355997eb43e8"}},"pubmed-pmid-18046908-sermorelin-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-18046908-sermorelin:v1","objectPathId":"pubmed-pmid-18046908-sermorelin-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-18046908-sermorelin/","json":"https://peptidescanner.com/evidence/v1/peptides/sermorelin.json#pubmed-pmid-18046908-sermorelin-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/sermorelin.md#pubmed-pmid-18046908-sermorelin-v1"},"story":{"slug":"pubmed-pmid-18046908-sermorelin","version":1,"domain":"Literature metadata","dateInSource":"2021-10-20","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["sermorelin"],"peptides":[{"slug":"sermorelin","url":"https://peptidescanner.com/peptides/sermorelin/"}]},"claims":[{"id":"headline","text":"Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?","sourceIds":["pubmed-observation-pmid-18046908-2021-10-20-daded1ed37f3"]},{"id":"summary","text":"PubMed lists PMID 18046908 in Clinical interventions in aging as Editorial, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug sermorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-18046908-2021-10-20-daded1ed37f3"]},{"id":"paragraph-1","text":"PubMed lists PMID 18046908 in Clinical interventions in aging as Editorial, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug sermorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-18046908-2021-10-20-daded1ed37f3"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-18046908-2021-10-20-daded1ed37f3"]}],"sources":[{"id":"pubmed-observation-pmid-18046908-2021-10-20-daded1ed37f3","name":"PubMed","sourceClass":"A","title":"Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? · retained source version 1:2021-10-20:current:daded1ed37f3a4740b3f8e1f6ea26cf01909ca7be57ee8ec8ae8953d210611d1","url":"https://pubmed.ncbi.nlm.nih.gov/18046908/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"7ca84ab008cce769667f06e774b0744f62e50c398caa474432fd8df28b2c62ee","tierARecordSha256":"0ae6aab89c60ddb29197a84efce595ef9564592458a44546506121048a1a4109"},"integrity":{"algorithm":"sha256","contentSha256":"bf3e4428d1be4272e3e53efc83068d3850f0559aa6948ca7ca245998d7013f79"}}}}
